Compare AstraZeneca plc (AZN) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Target Corporation — how do they compare? AstraZeneca plc trades at $168.99 (market cap $253.13B), while Target Corporation trades at $139.01 (market cap $60.86B). The key difference: AstraZeneca plc is far larger — about 4.2× Target Corporation's market cap, and Target Corporation pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| AZN | TGT | |
|---|---|---|
Market Cap | $253.13B | $60.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $141.19 |
52-Week Low | $137.44 | $83.68 |
Enterprise Value | $279.37B | $76.16B |
Dividend Yield | 1.92% | 3.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Target (TGT) trades at $134.77, down 0.27% today, with a bullish technical signal from moving averages and a neutral oscillator stance. The company maintains stable revenue around $106.6 billion (2025) and has beaten earnings estimates for three consecutive quarters. Recent dividend payments of $1.14 and $1.16 per share highlight its shareholder returns, while analyst consensus leans toward a buy rating with a $137 price target.
TGT presents a balanced opportunity with solid fundamentals and moderate valuation, but faces risks from competitive retail pressures and margin compression. Upside is supported by consistent earnings beats and dividend reliability, though investors should monitor consumer spending trends and inventory management challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
